Natural Alternatives International, Inc. is a formulator, maker and marketer of nutritional supplements. The company has market cap of $60.30 million. The Firm operates through three divisions: private-label contract manufacturing, patent and trademark licensing, and branded products. It has a 5.1 P/E ratio. The private-label contract manufacturing segment primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other healthcare products.
The stock of Sanofi SA (ADR) (NYSE:SNY) gapped up by $0.44 today and has $48.02 target or 6.00% above today’s $45.30 share price. The 8 months technical chart setup indicates low risk for the $117.66B company. The gap was reported on Mar, 27 by Barchart.com. If the $48.02 price target is reached, the company will be worth $7.06 billion more. About 2.05M shares traded or 39.46% up from the average. Sanofi SA (ADR) (NYSE:SNY) has risen 12.25% since August 18, 2016 and is uptrending. It has outperformed by 5.07% the S&P500.
Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $269,501 activity.
Analysts await Natural Alternatives International, Inc. (NASDAQ:NAII) to report earnings on May, 9.
Navellier & Associates Inc holds 0.07% of its portfolio in Natural Alternatives International, Inc. for 35,038 shares. Bridgeway Capital Management Inc owns 106,810 shares or 0.02% of their US portfolio. Moreover, Renaissance Technologies Llc has 0.01% invested in the company for 479,300 shares. The Arizona-based Tci Wealth Advisors Inc. has invested 0.01% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 1,669 shares.
About 8,941 shares traded. Natural Alternatives International, Inc. (NASDAQ:NAII) has declined 15.78% since August 18, 2016 and is downtrending. It has underperformed by 22.96% the S&P500.
Among 8 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Sanofi-aventis Sa had 10 analyst reports since October 15, 2015 according to SRatingsIntel. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, October 15 report. The firm earned “Buy” rating on Thursday, September 8 by Berenberg. The rating was downgraded by HSBC on Tuesday, May 3 to “Hold”. The firm has “Underperform” rating by BNP Paribas given on Thursday, December 10. The firm has “Neutral” rating given on Tuesday, September 13 by BNP Paribas. The company was upgraded on Thursday, May 12 by Barclays Capital. The rating was initiated by Goldman Sachs with “Neutral” on Monday, November 7. The rating was downgraded by Bernstein to “Mkt Perform” on Monday, November 9. The firm has “Neutral” rating by Piper Jaffray given on Friday, September 23.
